SO-YOUNG INTERNATIONAL news, videos and press releases
For more news please use our advanced search feature.
SO-YOUNG INTERNATIONAL - More news...
SO-YOUNG INTERNATIONAL - More news...
- So-Young Announces Receipt of Withdrawal of Buyer Group’s Going Private Proposal
- So-Young Reports Unaudited Second Quarter 2022 Financial Results
- So-Young to Report Second Quarter 2022 Financial Results on August 16, 2022
- So-Young Announces Receipt of Minimum Bid Price Notice from Nasdaq
- So-Young Reports Unaudited First Quarter 2022 Financial Results
- So-Young to Report First Quarter 2022 Financial Results on May 23, 2022
- So-Young Provides Update on Status under Holding Foreign Companies Accountable Act
- So-Young International Inc. Files Its Annual Report on Form 20-F
- So-Young Reports Unaudited Fourth Quarter and Fiscal Year 2021 Financial Results
- So-Young to Report Fourth Quarter and Full Year 2021 Financial Results on March 25, 2022
- HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
- HOOKIPA Pharma to Present at the H.C. Wainwright BioConnect Conference
- HOOKIPA Pharma to Participate in the JMP Securities Hematology and Oncology Summit
- So-Young Announces Engagement of Legal and Financial Advisors to the Special Committee
- So-Young Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
- So-Young Reports Unaudited Third Quarter Financial Results
- So-Young to Report Third Quarter 2021 Financial Results on November 19, 2021
- HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights
- HOOKIPA advances HB-200 program to Phase 2 and prioritizes oncology portfolio based on clinical data updates across its novel arenaviral platform
- HOOKIPA Pharma to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
- HOOKIPA announces publication on the benefits of its novel arenaviral immunotherapeutics in cancer in Frontiers in Oncology
- HOOKIPA announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced head and neck cancers
- So-Young Reports Unaudited Second Quarter Financial Results
- HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
- So-Young to Report Second Quarter 2021 Financial Results on September 10, 2021
- HOOKIPA Pharma Reports Second Quarter 2021 Financial Results and Recent Highlights
- Pre-clinical data on HOOKIPA’s arenaviral immunotherapeutic in melanoma published in Nature Communications
- HOOKIPA Pharma to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021
- So-Young International Inc. to Acquire Controlling Interest in Wuhan Miracle Laser Systems, Inc.
- HOOKIPA Pharma to Participate in Upcoming Investor Conferences in June
